Guardant Health, Inc. (GH)

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

Reviewing Guardant Health (NASDAQ:GH) & Privia Health Group (NASDAQ:PRVA)

The Top HealthTech Questions Landing on Our Desks

Reviewing Guardant Health (NASDAQ:GH) & CorVel (NASDAQ:CRVL)

AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.

Guardant Health (NASDAQ:GH) versus InfuSystem (NYSE:INFU) Critical Review

Guardant Health (NASDAQ:GH) Director Sells $144,550.00 in Stock

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

Business Insider Names Guardant Health One of America's Most Innovative Businesses

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Guardant Health's Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

Why Rule Breakers Buy a Stock That's Already "Won"

Bamco Inc. NY Makes New $2.48 Million Investment in Guardant Health, Inc. $GH

Callan Family Office LLC Invests $912,000 in Guardant Health, Inc. $GH